Caladrius (formerly NeoStem) CLBS 1.89 -0.02 -1.05% is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing.
June 29, 2015
Caladrius Biosciences Establishes Cardiovascular Scientific Advisory Board to Support Ongoing Development Efforts Using CD34 Cells
June 23, 2015
Jun 16, 2015
May 28, 2015
Pipeline & Capabilities
Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.